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Findingnewtargetstoimprovecurrentcancertherapiesis
one of the areas of Biomedicine and Biotechnology that gen-
erates greater expectations. The telomeres, special protective
structures at the end of eukaryotic chromosomes have been
metaphorically proposed to be cancer’s Achilles heel, since
they are essential to stabilize linear chromosomes [1]. There
is mounting evidence that loss of telomere function, either
by altering telomere-binding proteins or by loss of telom-
eric sequences,is associated with loss of cell viability through
induction of apoptosis [1]. Most of the attempts to impair
telomere function have consisted in the inhibition of the en-
zyme telomerase, a ribonucleoprotein DNA polymerase that
synthesizes telomeres, de novo [2]. The characterization of
mice that lack the RNA component of telomerase showed
that telomerase inhibition in a mammal leads to telomere
shortening, increased chromosomal instability, and loss of
viability [3]. Furthermore, inhibition of telomerase in vari-
ous cancer cell lines, either using dominant versions of the
enzyme or antisense oligonucleotides against the RNA com-
ponent, also lead to telomere shortening and cell death or
differentiation [4–6]. All these studies suggested that telom-
eraseinhibitionmightcompromisetumorgrowthbyleading
to an accelerated telomere shortening and cell death, hence,
anticancer therapies based in telomerase inhibition could be
a promising approach. Some data suggest, however, that the
situation may be more complex. The ﬁrst doubt thrown on
the efﬁcacy of an anticancer therapy based on telomerase in-
hibitioncamefromthefactthattelomerescanbemaintained
by means other than telomerase itself [7, 8]. Such telomere
maintenance mechanisms seem to be selected when telom-
eresreachacriticalshortlength,chromosomalabnormalities
have occurred and cell viability has been compromised [9].
In other words, even though telomerase inhibition in a tu-
mor might result in short telomeres and cell death, there is a
possibility that resistant clones might arise that would be re-
fractorytothetreatmentandwouldbearahigherchromoso-
malinstability.Thisissupportedbyevidencefromthemouse
model without telomerase:even though these mice show loss
of viability associated with telomere shortening, a fraction
of telomerase-deﬁcient mice appear to develop lymphomas
at a higher frequency than the wild-type counterparts [10].
These tumors are possibly the consequence of loss of check-
pointsassociatedwithtelomereloss,thisallowingthegrowth
of cells bearing high chromosomal instability and maintain-
ing telomeres without telomerase [11]. An analogous situa-
tion could happen in human cancers where the proliferative
pressure is very high. Such telomerase-independent telomere
maintenance mechanisms should be targeted if we want to
assure an efﬁcient telomere-based therapy. We have learned
fromstudiesinyeastthatthesemechanismsmightinvolveho-
mologous recombination and DNA repair proteins [12, 13].
More recently, it has been proposed that a special structure
at human telomeres, known as the telomeric loop, could
also account for telomerase-independent telomere elonga-
tion [14]. It is possible, however, that different tissues have
different sensitivities to telomere loss. In this regard,the skin
of telomerase-deﬁcient mice is resistant to chemical tumori-
genesis [15]. This supporting that telomerase inhibition in
skin tumors might cease their growth.
A second possible problem of a tumor therapy based on
telomerase inhibition is that tumor cells may divide with-
out telomerase before reaching critically short telomeres. In
other words,telomerase inhibition is not expected to have an
immediate effect on tumor growth.
In summary, there is strong evidence that telomeres may
be a very good target for new anticancer therapies. To date,
mostoftheeffortstocompromisetelomerefunctionincancer
cellshaveinvolvedtelomeraseinhibition.Thefactthattelom-
erescanalsobemaintainedinatelomerase-independentway
andthattelomereshavetoreachacriticallengthbeforeeffects
onviabilityareseen,mightresultinalowefﬁciencyof atreat-
ment based on telomerase inhibition. This should encourage
researchers to focus future studies not only on development
of telomerase inhibitors but also on inhibitors of telomeric
proteins, disruption of telomere structure, or disruption of
alternative telomere maintenance pathways.
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